Sign in now to view, license and download this image or contact us to see this image without a watermark. Want to embed this image on a non-commercial website or blog? Learn more.
Prozac capsule in foil packaging, close-up : Stock Photo
Drug (fluoxetine) used in treatment of depression, obsessive-compulsive disorders, etc. Introduced in 1986, by 1994, 10 million people worldwide using the drug. Mechanism not fully understood. Selective inhibitor of seretonin re-uptake by brain.

Prozac capsule in foil packaging, close-up

Credit: Steven Taylor
Caption:
Drug (fluoxetine) used in treatment of depression, obsessive-compulsive disorders, etc. Introduced in 1986, by 1994, 10 million people worldwide using the drug. Mechanism not fully understood. Selective inhibitor of seretonin re-uptake by brain.
Calculate priceView cart
Creative #:
BB1957-001
Release info:
Not released.More information
License type:
Rights-managedRights-managed products are licensed with restrictions on usage, such as limitations on size, placement, duration of use and geographic distribution. You will be asked to submit information concerning your intended use of the product, which will determine the scope of usage rights granted.
Collection:
The Image Bank
Max file size:
3,352 x 4,990 px (11.17 x 16.63 in) - 300 dpi - 5.69 MB

Keywords

This image is subject to copyright. Getty Images reserves the right to pursue unauthorized users of this image or clip, and to seek damages for copyright violations. To learn more about copyright and Getty Images’ enforcement program, click here. Availability for this image cannot be guaranteed until time of purchase.
Prozac Capsule In Foil Packaging Closeup Stock Photo BB1957-001Anti-Depressant,Blister Pack,Capital Letter,Capsule,Close-up,Color Image,Day,Depression,Drug Abuse,Healthcare And Medicine,Mental Illness,No People,Photography,Prozac,Sadness,Solution,Text,Vertical,Western ScriptPhotographer Collection: The Image Bank Drug (fluoxetine) used in treatment of depression, obsessive-compulsive disorders, etc. Introduced in 1986, by 1994, 10 million people worldwide using the drug. Mechanism not fully understood. Selective inhibitor of seretonin re-uptake by brain.